PallasPyro 🔥 أُعيد تغريده
🫀Heart failure in 2026: we are no longer treating symptoms. We are redesigning the disease.
The latest evidence update reminds us of something profound:
Heart failure is no longer a single entity.
It is a spectrum, and now, finally, we are treating it as one.
Several paradigm shifts stand out.
1. SGLT2 inhibitors are no longer “add-on” therapy.
They are foundational across the entire EF spectrum.
From HFrEF to HFpEF, the data are now consistent.
Not just symptom improvement, but hard outcomes.
This may be the most important unifying therapy in modern HF.
2. HFpEF is no longer a therapeutic desert.
For the first time, we have real disease-modifying options:
Finerenone → outcome reduction across EF ranges
GLP-1 / dual incretin therapies → targeting the obesity phenotype
Structural and metabolic mechanisms are finally being addressed
We are moving from “HFpEF frustration” → HFpEF phenotyping.
3. Acute heart failure is no longer about stabilization.
It is about early transformation.
The new paradigm:
Start GDMT in-hospital
Optimize rapidly
Treat beyond congestion
Decongestion is still important, but it is no longer the goal.
Disease modification starts on day 1.
4. Decongestion is becoming precision medicine
Urine sodium-guided therapy
Early escalation of loop diuretics
Sequential nephron blockade
Not just “give furosemide”, but measure, adjust, and target response.
5. Devices are no longer rescue therapy, they are integrated care
TEER expanding from mitral → tricuspid
Pulmonary artery pressure monitoring reducing hospitalizations
Remote hemodynamics shaping outpatient management
The boundary between ICU, ward, and home is dissolving.
6. The biggest problem is no longer evidence.
It is implementation.
We already have:
Quadruple therapy
Proven outcome benefits
Yet many patients never reach target doses.
The gap is no longer science.
It is execution.
🤓Final message
Heart failure care has entered a new era:
Mechanism-based therapy
Early aggressive optimization
Phenotype-driven treatment
And perhaps most importantly:
We are no longer chasing symptoms.
We are altering the trajectory of the disease.
📃Reference
Liori S, et al. Heart failure evidence update 2026. Heart Failure Reviews. 2026. doi.org/10.1007/s10741…
English
